Litcius/Paper detail

Modulation of autophagy: a Phase II study of vorinostat plus hydroxychloroquine versus regorafenib in chemotherapy-refractory metastatic colorectal cancer (mCRC)

Sukeshi Patel Arora, Laura Tenner, John Sarantopoulos, Jay Morris, Qianqian Liu, Jenny Mendez, Tyler J. Curiel, Joel Michalek, Devalingam Mahalingam

2022British Journal of Cancer39 citationsDOIOpen Access PDF

Topics & Concepts

MedicineRegorafenibHydroxychloroquineColorectal cancerInternal medicineVorinostatOncologyAfliberceptAdverse effectBevacizumabClinical endpointCancerChemotherapyClinical trialHistone deacetylaseBiologyBiochemistryHistoneCoronavirus disease 2019 (COVID-19)Infectious disease (medical specialty)GeneDiseaseAutophagy in Disease and TherapyHistone Deacetylase Inhibitors ResearchColorectal Cancer Treatments and Studies
Modulation of autophagy: a Phase II study of vorinostat plus hydroxychloroquine versus regorafenib in chemotherapy-refractory metastatic colorectal cancer (mCRC) | Litcius